绿竹生物-B(02480)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02480 绿竹生物-B

休市中 08-28 13:37:20

13.600

+0.000

0.00%

最高13.600	最低13.600	成交量200.00
今开13.600	昨收13.600	日振幅0.00%
总市值27.06亿	流通市值27.06亿	总股本1.99亿
成交额2,720	换手率0.00%	流通股本1.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02480","market":"HK","secType":"STK","nameCN":"绿竹生物-B","latestPrice":13.6,"timestamp":1787895440392,"preClose":13.6,"halted":0,"volume":200,"delay":0,"changeRate":0,"floatShares":199000000,"shares":199000000,"eps":-0.873753175872777,"marketStatus":"休市中","change":0,"latestTime":"08-28 13:37:20","open":13.6,"high":13.6,"low":13.6,"amount":2720,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.7844579313070481,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":7,"adr":0,"listingDate":1683475200000,"exchange":"SEHK","adjPreClose":13.6,"openAndCloseTimeList":[[1787880600000,1787889600000],[1787893200000,1787904000000]],"volumeRatio":0.33333330000000333,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02480","defaultTab":"news","newsList":[{"id":"1137355516","title":"绿竹生物-B2026年中期财报：其他收入约676.20万元，同比增长39.4%，非公认会计准则口径净亏损约6,162.20万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137355516","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137355516?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:38","pubTimestamp":1787733500,"startTime":"0","endTime":"0","summary":"根据最新公告，绿竹生物-B在2026年上半年取得其他收入约676.20万元，同比增长39.4%。公司同期经非公认会计准则口径测算的净亏损约6,162.20万元，与去年同期相比下降20.6%，亏损幅度有所收窄。公告显示，绿竹生物-B在本期行政开支约2,828.90万元，同比增长9.6%；研发费用约3,033.10万元，同比降低39.7%。公司表示，研发投入的变化主要系在研产品处于不同临床阶段导向所致。经营活动所用现金净额为4,560.80万元，相较于上年同期的7,528.50万元有所改善。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"绿竹生物-B2026年中期财报：其他收入约676.20万元，同比增长39.4%，非公认会计准则口径净亏损约6,162.20万元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662796287","title":"绿竹生物-B(02480.HK)公布中期业绩 净亏损6162.2万元 同比减少20.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662796287","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662796287?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:34","pubTimestamp":1787733241,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121927689","title":"绿竹生物-B（02480）计划8月26日审议2026年中期业绩及派息议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1121927689","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121927689?lang=zh_cn&edition=full","pubTime":"2026-08-14 16:46","pubTimestamp":1786697191,"startTime":"0","endTime":"0","summary":"绿竹生物-B（02480）8月14日公告称，公司董事会拟于2026年8月26日（星期三）召开会议，届时将审议并批准本集团截至2026年6月30日止六个月的未经审计合并中期业绩，并讨论是否派发中期股息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161296280","title":"绿竹生物-B：彭玲减持，好仓比例降至5.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161296280","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161296280?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:13","pubTimestamp":1786525985,"startTime":"0","endTime":"0","summary":"彭玲于2026年1月7日以每股均价23.0000港元卖出绿竹生物-B股份5.00万股，涉资约115.00万港元。彭玲此次减持前持有绿竹生物-B好仓1175.97万股，占比5.81%；减持后持股量为1170.97万股，好仓比例降至5.78%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658842672","title":"绿竹生物-B(02480.HK)于Nature Communications发表LZ901 III期临床试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2658842672","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658842672?lang=zh_cn&edition=full","pubTime":"2026-08-09 18:29","pubTimestamp":1786271377,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181566683","title":"绿竹生物-B（02480）核心产品LZ901Ⅲ期临床数据发表于《Nature Communications》 总体保护效力91.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181566683","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181566683?lang=zh_cn&edition=full","pubTime":"2026-08-09 18:25","pubTimestamp":1786271141,"startTime":"0","endTime":"0","summary":"北京绿竹生物技术股份有限公司8月9日发布自愿性公告称，其核心产品、在研重组带状疱疹疫苗LZ901的中国Ⅲ期临床试验结果已于2026年8月7日发表于国际期刊《Nature Communications》。本次Ⅲ期临床为多中心、随机、双盲、安慰剂对照研究，用于评估LZ901在40岁及以上成人中预防带状疱疹的有效性及安全性。根据香港联合交易所有限公司证券上市规则第18A.05条，公司无法保证LZ901最终能够成功获得批准并实现商业化。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131409078","title":"绿竹生物-B发布7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1131409078","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131409078?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:41","pubTimestamp":1785832914,"startTime":"0","endTime":"0","summary":"2026年8月4日，北京绿竹生物技术股份有限公司披露了截至2026年7月31日的股份变动月报。报告期为2026年7月1日至7月31日。报告显示，公司的法定（注册）股本在期内未发生任何变动，依旧为人民币202,449,032元。公司确认，截至2026年7月31日，已经满足适用的公众持股量要求。本次公告由公司秘书刘斯宇签署。公司同时表示，所有已发行的股份变动均严格遵守香港联交所《上市规则》及相关法律法规的要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100993086","title":"绿竹生物-B公布6月股份变动月报，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1100993086","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100993086?lang=zh_cn&edition=full","pubTime":"2026-07-03 12:16","pubTimestamp":1783052176,"startTime":"0","endTime":"0","summary":"北京绿竹生物技术股份有限公司于2026年7月3日披露6月股份变动月报，报告期为截至2026年6月30日。公告显示，公司本月期间并无新增发行、回购或注销股份，股本结构保持稳定。根据公告，绿竹生物-B于报告期末普通股H股的法定/注册股本为人民币2.02亿元，与上个月持平。其中，已发行股份数量198,913,232股，库存股份数目3,535,800股，合计202,449,032股，较上月同样无变化。公司确认已符合截至本月末的适用公众持股量要求。本次月报由公司秘书刘斯宇签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189031804","title":"绿竹生物-B5月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1189031804","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189031804?lang=zh_cn&edition=full","pubTime":"2026-06-02 16:47","pubTimestamp":1780390041,"startTime":"0","endTime":"0","summary":"绿竹生物-B于2026年6月2日发布2026年5月31日止当月证券变动月报。公告显示，公司法定/注册股本与已发行股本在本月无变化，均保持在202,449,032股，面值每股人民币1元。截至2026年5月31日，绿竹生物-B普通股H股的已发行股份数量为198,913,232股，库存股份数量为3,535,800股，合计股本总数为202,449,032股，与上月底持平。报告期内无新增发行、购回、注销或库藏股份变动。本月内未发生涉及股份期权、股权激励或可转债的变动事项。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100400703","title":"绿竹生物-B拟回购不超10%已发行H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1100400703","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100400703?lang=zh_cn&edition=full","pubTime":"2026-05-18 21:51","pubTimestamp":1779112297,"startTime":"0","endTime":"0","summary":"绿竹生物-B公告，将于2026年6月12日召开股东大会，审议并酌情批准授予董事股份购回授权。根据公告，该公司计划回购不超过截止股东大会通告日已发行H股总数10%的股份，即最多回购19,891,323股H股。公司称，回购所涉资金将遵循相关法规与公司章程，确保合法来源。董事会认为，此举旨在维护股东权益，优化公司资本结构，提高每股盈利水平，符合公司及其股东的整体最佳利益。公司提示，持有库存股份的投资者须就所持库存股份放弃该次表决权。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"绿竹生物-B拟回购不超10%已发行H股","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190377765","title":"绿竹生物-B4月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1190377765","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190377765?lang=zh_cn&edition=full","pubTime":"2026-05-05 16:38","pubTimestamp":1777970318,"startTime":"0","endTime":"0","summary":"绿竹生物-B于2026年5月5日发布2026年4月的股份变动月报表。报告显示，截至2026年4月30日，公司普通股H股的法定/注册股本为202,449,032股，每股面值人民币1元，总额人民币202,449,032元。其中，已发行股份为198,913,232股，库存股份3,535,800股，合计202,449,032股，与上月末持平。本月未发生新增发行、购回或注销股份事宜，股本规模整体保持稳定。公司重申，其所有证券发行、股份变动均符合香港联交所《上市规则》和相关法律规定。公司表示，将继续依法合规履行信息披露义务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169475293","title":"绿竹生物-B2025年度：亏损收窄至1.50亿元，带状疱疹疫苗等核心管线稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1169475293","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169475293?lang=zh_cn&edition=full","pubTime":"2026-04-23 22:46","pubTimestamp":1776955588,"startTime":"0","endTime":"0","summary":"绿竹生物-B在截至2025年12月31日止年度内，年内亏损为人民币1.50亿元，较上一年度的人民币1.68亿元减少10.6%，主要源于行政及研发开支双双下降。行政开支同比减少20.1%至约人民币5,179万元，研发开支同比下降28.6%至约人民币9,648万元，显示公司对内部成本结构进行了明显优化。年内，公司持续聚焦创新型疫苗与生物制剂的研发和商业化，带状疱疹疫苗LZ901为核心产品，已在国内与海外多地推进临床试验并提交上市申请相关资料。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"绿竹生物-B2025年度：亏损收窄至1.50亿元，带状疱疹疫苗等核心管线稳步推进","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171835236","title":"绿竹生物-B3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1171835236","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171835236?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:51","pubTimestamp":1775119863,"startTime":"0","endTime":"0","summary":"绿竹生物-B于2026年4月2日发布截至2026年3月31日的股份变动月报表。报告显示，公司本月并无新增发行、回购、注销或库存股份方面的变动，股本整体保持稳定。截至3月末，公司普通股股本总数为202,449,032股，其中已发行股份198,913,232股，库存股份3,535,800股，与上月底持平。公司同时确认严格遵守香港联交所《上市规则》及适用法律法规，相关证券发行及库存股份交易均获得董事会正式授权并履行相应程序。公司表示，将继续按规定及时披露股份变动及相关信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620725528","title":"绿竹生物-B(02480)公布2025年业绩 净亏损约1.5亿元 同比减少10.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620725528","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2620725528?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:40","pubTimestamp":1773837619,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿竹生物-B 公布2025年业绩，其他收入约1103.1万元，同比减少48.4%;研发开支9647.5万元，同比减少28.6%;净亏损约1.5亿元，同比减少10.6%。于2025年 1月，集团向国家药监局提交了其核心产品LZ901的BLA，并随后于2025年2 月获受理。于2025年第三季度，国家药监局完成了临床试验现场核查及生产现场检查等程序。截至本公告日期，国家药监局仍在审查LZ901的BLA。LZ901只有在获得BLA批准及批签发证明后方可进行商业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02480","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620232169","title":"绿竹生物-B(02480)：赖浩恩获委任为联席公司秘书、授权代表及法律程序代理人","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232169","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2620232169?lang=zh_cn&edition=full","pubTime":"2026-03-18 18:42","pubTimestamp":1773830557,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿竹生物-B(02480)发布公告，袁颕欣女士(袁女士)已辞任本公司的联席公司秘书及根据香港联合交易所有限公司证券上市规则第 3.05条的本公司的授权代表(授权代表)、香港法例第 622章《公司条例》第16部所规定本公司于香港的授权代表及上市规则第19A.13(2) 条所规定于香港接收法律程序文件及通知书的授权人士(法律程序代理人)， 自2026年3月18日起生效。于袁女士辞任后，董事会进一步欣然宣布赖浩恩女士(赖女士)获委任为本公司的联席公司秘书、授权代表及法律程序代理人，自2026年3月18日起生效。刘斯宇先生(刘先生)将继续担任另一位联席公司秘书。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02480","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618679060","title":"绿竹生物-B盘中异动 急速下挫9.47%报22.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618679060","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2618679060?lang=zh_cn&edition=full","pubTime":"2026-03-09 15:25","pubTimestamp":1773041152,"startTime":"0","endTime":"0","summary":"2026年03月09日下午盘15时25分，绿竹生物-B股票出现异动，股价快速下挫9.47%。截至发稿，该股报22.000港元/股，成交量400股，换手率0.00%，振幅7.41%。资金方面，该股资金流入9160港元，流出0港元。绿竹生物-B股票所在的生物技术行业中，整体跌幅为2.73%。其临床阶段在研产品包括重组带状疱疹疫苗LZ901,以及抗体注射产品K3和K193。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。该公司在中国国内市场和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030915255297aadfda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030915255297aadfda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616533513","title":"绿竹生物-B(02480.HK)拟3月18日举行董事会会议批准年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2616533513","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2616533513?lang=zh_cn&edition=full","pubTime":"2026-03-04 17:07","pubTimestamp":1772615223,"startTime":"0","endTime":"0","summary":"格隆汇3月4日丨绿竹生物-B(02480.HK)宣布，本公司将于2026年3月18日(星期三)举行董事会会议，以(其中包括)考虑及批准本集团截至2025年12月31日止年度的全年业绩以及考虑派发末期股息(如有)的建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260304/32044407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02480","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518571320","title":"绿竹生物-B03月11日主力净流入19万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2518571320","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518571320?lang=zh_cn&edition=full","pubTime":"2025-03-11 16:16","pubTimestamp":1741680990,"startTime":"0","endTime":"0","summary":"03月11日, 绿竹生物-B股价涨6.58%，报收24.30元，成交金额102万元，换手率0.02%，振幅6.14%，量比32.87。绿竹生物-B今日主力资金净流入19万元，上一交易日主力净流出0万元。该股近5个交易日上涨15.99%，主力资金累计净流入19万元；近20日主力资金累计净流入19万元，其中净流入天数为1日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311165944abf609cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311165944abf609cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518175326","title":"绿竹生物-B盘中异动 快速上涨6.58%报24.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518175326","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518175326?lang=zh_cn&edition=full","pubTime":"2025-03-11 10:50","pubTimestamp":1741661433,"startTime":"0","endTime":"0","summary":"2025年03月11日早盘10时50分，绿竹生物-B股票出现异动，股价快速拉升6.58%。截至发稿，该股报24.300港元/股，成交量2600股，换手率0.00%，振幅5.70%。资金方面，该股资金流入6.27万港元，流出0港元。绿竹生物-B股票所在的生物技术行业中，整体涨幅为1.44%。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031110503398a345d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031110503398a345d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518298889","title":"绿竹生物-B盘中异动 快速上涨5.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518298889","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518298889?lang=zh_cn&edition=full","pubTime":"2025-03-10 13:33","pubTimestamp":1741584786,"startTime":"0","endTime":"0","summary":"2025年03月10日下午盘13时33分，绿竹生物-B股票出现波动，股价急速上涨5.86%。绿竹生物-B股票所在的生物技术行业中，整体跌幅为2.67%。绿竹生物-B公司简介：北京绿竹生物技术股份有限公司是一家主要从事药物发现、研究及开发及商业化的中国公司。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310133306963fba33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310133306963fba33&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://luzhubiotech.com","stockEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":-0.032},{"period":"3month","weight":-0.2909},{"period":"6month","weight":-0.4516},{"period":"1year","weight":-0.4458},{"period":"ytd","weight":-0.4237}],"compareEarnings":[{"period":"1week","weight":-0.0163},{"period":"1month","weight":-0.0086},{"period":"3month","weight":0.016},{"period":"6month","weight":-0.0393},{"period":"1year","weight":0.0234},{"period":"ytd","weight":-0.0018}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"北京绿竹生物技术股份有限公司是一家主要从事疫苗及治疗性生物制剂的研究、开发及生产的中国公司。该公司还从事开发创新型人用疫苗及治疗性生物制剂，以预防及控制传染病以及治疗癌症及自身免疫性疾病。该公司的产品包括临床阶段的在研产品，以及临床前阶段的在研产品。核心产品LZ901，主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。该公司主要在国内市场开展其业务","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.015264},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.050755},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.053698},{"month":4,"riseRate":0.666667,"avgChangeRate":0.180538},{"month":5,"riseRate":0,"avgChangeRate":-0.1833},{"month":6,"riseRate":0.75,"avgChangeRate":0.061327},{"month":7,"riseRate":0.5,"avgChangeRate":-0.008037},{"month":8,"riseRate":0.5,"avgChangeRate":0.048602},{"month":9,"riseRate":0.666667,"avgChangeRate":-0.010717},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.04693},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.013518},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.018225}],"exchange":"SEHK","name":"绿竹生物-B","nameEN":"LUZHU BIOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"绿竹生物-B(02480)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供绿竹生物-B(02480)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"绿竹生物-B,02480,绿竹生物-B股票,绿竹生物-B股票老虎,绿竹生物-B股票老虎国际,绿竹生物-B行情,绿竹生物-B股票行情,绿竹生物-B股价,绿竹生物-B股市,绿竹生物-B股票价格,绿竹生物-B股票交易,绿竹生物-B股票购买,绿竹生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"绿竹生物-B(02480)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供绿竹生物-B(02480)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}